HENDERSON, Nev. / Sep 17, 2025 / Business Wire / P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming Jefferies Healthcare Services Conference.
Management will participate in a fireside chat on Tuesday, September 30, 2025, at 2:25 PM Central Time. A webcast of the presentation will be available on P3’s Investor Relations Website at https://ir.p3hp.org/. A replay will be available on P3’s investor relations webpage for 30 days following the presentation.
About P3 Health Partners (NASDAQ: PIII):
P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,800 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 27 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. For more information, visit https://p3hp.org/ and follow us on LinkedIn and Facebook.com/p3healthpartners.
Last Trade: | US$8.79 |
Daily Change: | -0.19 -2.12 |
Daily Volume: | 513 |
Market Cap: | US$28.730M |
August 25, 2025 August 14, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load